229LG, Associate Director / Senior Scientist, In Vivo Pharmacology

Job Code 229LG

Description

Fate Therapeutics is seeking a highly motivated in vivo pharmacologist to join a multidisciplinary team dedicated to the discovery of novel cellular therapies. The qualified candidate is a highly motivated, interactive, and creative individual that possesses the ability to work across a highly matrixed environment to advance preclinical programs from target identification/validation through IND enabling activities. The candidate will develop novel animal models that more closely mimic human cancer and answer mechanistic questions, validate early targets that have the potential to progress, and test and screen drug candidates using a wide range of animal models including syngeneic, CDX and, potentially, GEMM models. Specifically, this position will work with other research and development groups and program group leaders to prioritize and coordinate efficient use of the in vivo department facilities, equipment, and staff. The position requires excellent people management skills with in-depth knowledge of in vivo pharmacology, cell therapy, rodent models of human disease and preclinical imaging and histology. This is a full-time position in In Vivo Pharmacology located at the Company’s corporate headquarters in San Diego, California.

Download a PDF of the job description for more details:

View PDF

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 229LG.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.